BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. Financials Biohaven Pharmaceutical Holding Company Ltd.
Equities
BHVN
VGG111961055
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.97 USD | +1.12% |
|
-0.05% | -74.33% |
| Apr. 25 | Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing | MT |
| Apr. 23 | Biohaven Shares Rise After Closing of Public Offering, Disclosure of Stock Purchase by CEO | MT |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Capitalization 1 | 971.8 | 1,615 | 2,844 | 5,137 | 9,027 |
| Enterprise Value (EV) 1 | 840.3 | 1,469 | 2,775 | 5,570 | 9,887 |
| P/E ratio | -5.4 x | -6.02 x | -4.99 x | -6.56 x | -10.5 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 80,742,231 x | 19,516,872 x |
| EV / Revenue | - | - | - | 87,534,473 x | 21,377,123 x |
| EV / EBITDA | -7.81 x | -6.55 x | -5.8 x | -8.76 x | -14.5 x |
| EV / FCF | -15.5 x | -11.5 x | -12.1 x | -10.5 x | -26 x |
| FCF Yield | -6.44% | -8.68% | -8.25% | -9.52% | -3.85% |
| Price to Book | 7.37 x | 10.8 x | -384 x | -13.3 x | -12.5 x |
| Nbr of stocks (in thousands) | 36,018 | 43,683 | 52,240 | 59,939 | 65,501 |
| Reference price 2 | 26.98 | 36.98 | 54.44 | 85.71 | 137.8 |
| Announcement Date | 3/6/18 | 2/28/19 | 2/26/20 | 3/1/21 | 2/25/22 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | 63.63 | 462.5 |
| EBITDA 1 | -60.63 | -107.5 | -224.3 | -478.5 | -635.9 | -679.6 |
| EBIT 1 | -60.64 | -107.6 | -224.6 | -479.1 | -645.4 | -704 |
| Operating Margin | - | - | - | - | -1,014.33% | -152.22% |
| Earnings before Tax (EBT) 1 | -63.44 | -138.2 | -240.5 | -528.4 | -758.4 | -843.3 |
| Net income 1 | -63.68 | -139.2 | -240.9 | -528.8 | -766.8 | -846.6 |
| Net margin | - | - | - | - | -1,205.14% | -183.04% |
| EPS 2 | -5.050 | -4.999 | -6.148 | -10.91 | -13.06 | -13.09 |
| Free Cash Flow 1 | -30.2 | -54.1 | -127.5 | -229 | -530.2 | -380.2 |
| FCF margin | - | - | - | - | -833.23% | -82.21% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/7/17 | 3/6/18 | 2/28/19 | 2/26/20 | 3/1/21 | 2/25/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 432 | 860 |
| Net Cash position 1 | 18.8 | 131 | 147 | 69 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.6796 x | -1.266 x |
| Free Cash Flow 1 | -30.2 | -54.1 | -127 | -229 | -530 | -380 |
| ROE (net income / shareholders' equity) | 18,797% | -214% | -170% | -737% | 453% | 167% |
| ROA (Net income/ Total Assets) | -262% | -77.3% | -64.2% | -94.4% | -78.2% | -49.9% |
| Assets 1 | 24.29 | 180 | 375 | 560 | 980.2 | 1,697 |
| Book Value Per Share 2 | -3.440 | 3.660 | 3.410 | -0.1400 | -6.460 | -11.00 |
| Cash Flow per Share 2 | 1.800 | 3.650 | 5.980 | 6.050 | 2.190 | 2.570 |
| Capex 1 | 0.03 | 0.54 | 4.17 | 3.78 | 3.97 | 1.72 |
| Capex / Sales | - | - | - | - | 6.24% | 0.37% |
| Announcement Date | 4/7/17 | 3/6/18 | 2/28/19 | 2/26/20 | 3/1/21 | 2/25/22 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -74.33% | 541M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BHVN Stock
- Financials Biohaven Pharmaceutical Holding Company Ltd.
